4.3 Article

Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach

Journal

PULMONARY PHARMACOLOGY & THERAPEUTICS
Volume 35, Issue -, Pages 8-16

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pupt.2015.09.007

Keywords

Inflammation; Preclinical models; Pulmonary arterial hypertension; Vascular remodeling

Funding

  1. Fundacao para a Ciencia e a Tecnologia (FCT, Portugal)
  2. European Union
  3. QREN
  4. FEDER
  5. COMPETE [PEst-C/QUI/UI0062/2013]
  6. Cardiovascular RD Unit [PEst-C/SAU/UI0051/2011]
  7. [SFRH/BD/91067/2012]
  8. Fundação para a Ciência e a Tecnologia [SFRH/BD/91067/2012] Funding Source: FCT

Ask authors/readers for more resources

Pulmonary arterial hypertension (PAH) is responsible for the premature death mainly because of progressive and severe heart failure. This disease is characterized by increased pulmonary vascular tone, inflammatory cell infiltration, vascular remodeling and occlusion of vessels with thrombi, frequently leading to right heart failure. Aiming to better comprehend the complexity of PAH and find novel therapeutic strategies or improve the existing ones, a variety of preclinical models have emerged. Although there is no ideal preclinical model of PAH currently available, animal models have been used to assist in the identification of the molecular pathways underlying PAH development and progression, and in the identification of novel therapeutics. Among preclinical models of PAH, monocrotaline (MCT) animal model offers the advantage of mimic several key aspects of human PAH, including vascular remodeling, proliferation of smooth muscle cells, endothelial dysfunction, upregulation of inflammatory cytokines, and right ventricle failure, requiring a single drug injection. This review summarizes the advantages and limitations of MCT animal model to the study of the molecular mechanisms underlying PAH pathogenesis, envisioning to improve the diagnosis and management of this complex disease. (C) 2015 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available